+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Combined human papillomavirus DNA and human papillomavirus-like particle serologic assay to identify women at risk for high-grade cervical intraepithelial neoplasia



Combined human papillomavirus DNA and human papillomavirus-like particle serologic assay to identify women at risk for high-grade cervical intraepithelial neoplasia



International Journal of Cancer 120(1): 55-59



The objective of this study was to assess the utility of a second generation human papillomavirus (HPV) virus-like particle (VLP)-based ELISA as an adjunct to HPV DNA testing to identify women at risk for high-grade cervical intraepithelial neoplasia (CIN). Participants provided blood, cervical samples and interviewer-obtained questionnaire information. HPV VLPs for types 16, 18, 33, 45 and 52 were produced using a baculovirus expression system. These highly purified VLPs were used in a polymer-based ELISA test. Cases with biopsy-confirmed CIN (CIN I, n = 237; CIN II, n = 56; CIN III, n = 48) and controls (n = 351) with normal Pap smears were tested for HPV DNA by PCR and serologic response to multiple oncogenic HPV VLPs. 258/341 (76%) of cases and 230/351 (65.5%) of control patients had any type of HPV VLP antibody (OR = 1.63, 95% CI 1.16-2.30). More cases were seropositive than controls for each individual HPV type (p < 0.001 for HPV types 16, 18, 33 and 45; p = 0.06 for HPV 52). Reactivity to an increasing number of different HPV type-specific VLPs are associated with high-grade CIN independent of HPV DNA status. HPV VLP assays may be useful as an adjunct to HPV DNA testing in a subset of patients that needs to be defined by further studies.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 012845659

Download citation: RISBibTeXText

PMID: 17036320

DOI: 10.1002/ijc.22176


Related references

Serologic response to human papillomavirus 16 among Australian women with high-grade cervical intraepithelial neoplasia. International Journal of Gynecological Cancer 16(3): 1032-1035, 2006

Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials. Lancet 369(9576): 1861-1868, 2007

Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials. Yearbook of Dermatology and Dermatologic Surgery 2008: 151-152, 2008

Prevalence of types 16 and 33 is increased in high-risk human papillomavirus positive women with cervical intraepithelial neoplasia grade 2 or worse. International Journal of Cancer 117(2): 177-181, 2005

Self-reported human papillomavirus vaccination does not have an impact on the risk for high-grade cervical intraepithelial neoplasia among women referred for colposcopy. American Journal of Obstetrics and Gynecology 215(1): 123-126, 2018

Hybrid Capture II testing for high-risk human papillomavirus DNA in the follow-up of women treated for high-grade cervical intraepithelial neoplasia. Journal of Lower Genital Tract Disease 17(3): 308-314, 2014

Human papillomavirus combined with cytology and margin status identifies patients at risk for recurrence after conization for high-grade cervical intraepithelial neoplasia. European Journal of Gynaecological Oncology 36(3): 245-251, 2015

Long-term risk of cervical intraepithelial neoplasia grade 3 or worse according to high-risk human papillomavirus genotype and semi-quantitative viral load among 33,288 women with normal cervical cytology. International Journal of Cancer 137(1): 193-203, 2015

Risk factors for human papillomavirus persistence among women undergoing cold-knife conization for treatment of high-grade cervical intraepithelial neoplasia. International Journal of Gynaecology and Obstetrics: the Official Organ of the International Federation of Gynaecology and Obstetrics 125(3): 275-278, 2015

Oral Human Papillomavirus in Women With High-Grade Cervical Intraepithelial Neoplasia. Journal of Lower Genital Tract Disease 21(3): 177-183, 2017

Human papillomavirus type-specific 18-month risk of high-grade cervical intraepithelial neoplasia in women with a normal or borderline/mildly dyskaryotic smear. Cancer Epidemiology, Biomarkers & Prevention 15(7): 1268-1273, 2006

Human papillomavirus 16 and 18 L1 serology in Korean women with high-grade cervical intraepithelial neoplasia and cervical cancer. Archives of Pharmacal Research 32(7): 1013-1018, 2009

High-risk human papillomavirus type does not predict grade of cervical intraepithelial neoplasia. European Journal of Gynaecological Oncology 24(5): 373-376, 2003

Risk for high-grade cervical intraepithelial neoplasia associated with variants of human papillomavirus types 16 and 18. Cancer Epidemiology, Biomarkers and Prevention 16(1): 4-10, 2007

Human papillomavirus 16 in breast cancer of women treated for high grade cervical intraepithelial neoplasia (CIN III). Breast Cancer Research and Treatment 53(2): 121-135, 1999